Roivant Sciences Ltd. (ROIV) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in London, United Kingdom. The current CEO is Matthew Gline.
ROIV has IPO date of 2020-12-08, 908 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $20.84B.
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company headquartered in London that researches and develops innovative medicines across multiple therapeutic areas. The company's pipeline includes product candidates targeting oncologic malignancies, rare genetic disorders such as sickle cell disease and hypophosphatasia, and various inflammatory and dermatological conditions including psoriasis, atopic dermatitis, and vitiligo. Additional focus areas encompass autoimmune diseases, ophthalmologic disorders, and infectious diseases. Founded in 2014, Roivant combines drug development expertise with healthcare technology capabilities to address significant unmet medical needs globally.
